Suggested Remit: To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer.
- Status:
- In progress
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1261
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 March 2020 | Note added to the project documents |
| 17 January 2020 | Note added to the project documents |
| 09 February 2018 | In progress. Topic referred 22 July 2016 |
For further information on our processes and methods, please see our CHTE processes and methods manual